COMPARISON / DIFFERENT HEALTH PROBLEMS
Why do these four substances need different studies?
The substances were tested for different problems, so one set of results cannot replace another. Who received treatment and what changed both matter. Your health concern gives the comparison its purpose.
Shows why findings for one problem cannot answer another
Are these substances choices for the same illness? The studies address different problems and cannot provide that kind of comparison. Semaglutide imitates GLP-1, a gut hormone carrying messages after food, and has large human trials. GHK-Cu research mainly concerns small cream studies and laboratory work on skin. NAD+ helps cells get energy from food, but trials often give ingredients used to make NAD+ [13]. PT-141, also named bremelanotide, is approved for a specific sexual-desire problem in women before menopause [22].
Your reason for considering treatment determines which studies are relevant.
Losing weight, having smoother skin, and avoiding a heart attack describe different benefits. More NAD+ in blood is a test finding, without necessarily showing a benefit. Prescription medicines, creams, and supplements also undergo different checks. For PT-141 and the other substances, your doctor can check who took part and which harms occurred. Comparing these findings helps establish what evidence exists for a health question. That comparison can't choose a treatment without also assessing the person.
Sets each measured change beside its main uncertainty
| substance | What the substance does | Where the evidence comes from | What changed or was measured | Main uncertainty or risk |
|---|---|---|---|---|
| Semaglutide | Imitates GLP-1, a gut hormone affecting blood sugar and hunger. | Large trials compared groups receiving different treatments [2][3][4]. | Researchers measured weight and counted serious illness involving kidneys and the heart. | Stomach and bowel symptoms, gallbladder disease, and diabetic eye damage matter [5][7]. |
| GHK-Cu | Holds copper and may affect proteins involved in skin repair. | Small skin studies, a mixed hair product, reviews, and tests on removed human skin [8][10][11][12]. | Studies examined skin appearance, hair counts, and passage of ingredients into skin. | Benefits and safety of injections cannot be established by cream studies. |
| NAD+ | Cells use NAD+ when drawing energy from food and repairing damage. | Trials gave NMN or NR, ingredients used to make NAD+, by mouth [13][14][15][17]. | Researchers measured NAD+ in blood, walking, and muscle response to insulin, which helps cells take up sugar. | More NAD+ in blood does not prove better health or long-term safety. |
| PT-141 | Affects brain activity involved in sexual desire. | Phase 3 trials, later testing, brain scans, and the prescribing label [19][20][21][22]. | Women before menopause reported desire and distress from lasting low interest in sex. | Approval is narrow; nausea, raised blood pressure, and skin darkening limit use. |
Checks whether cell changes also helped people
Semaglutide's effects on hunger and sugar gave researchers reasons to test weight and health. Trials then measured weight loss and counted severe illness involving people's kidneys and hearts [2][3][4]. GHK-Cu research found changes involving cells that make collagen and other skin proteins [9][11]. Those cell tests did not show that people developed healthier skin. A possible explanation needs tests in people before a health benefit is established.
The question for your doctor is whether people improved, rather than whether cells changed.
Cells depend on NAD+, but that need alone doesn't show benefits from taking extra. Related supplements increased NAD+ in blood, while a review found inconsistent evidence of health gains [13][14][17]. PT-141 trials asked a different question about women distressed by low sexual desire [19][20]. The doctor can check whether each study included similar people and fairly compared treatments. The length of the study and reported harms also affect what its results mean.
Distinguishes firmer human findings from early laboratory findings
Semaglutide trials involving thousands of people give firmer answers about weight and serious illness [2][3][4]. GHK-Cu has smaller skin studies and laboratory tests of removed skin [8][10][12]. NMN and NR studies found increases in blood NAD+, while wider health benefits remain uncertain [13][14][17]. PT-141 studies concern women troubled by low sexual desire [20]. Those results cannot show benefits for men or everyone seeking greater sexual interest.
How much a result tells you depends on what the researchers actually checked.
For a health concern, the doctor can ask whether symptoms improved or just a test changed. A comparison group may receive placebo with no active medicine, so differences can be checked. The exact ingredient, the way it entered the body, and the health of the people tested all matter. Your doctor can compare these details with the treatment being considered and your medical history. A broad promise alone cannot tell you those facts.
Helps bring a specific health question to the doctor
A note for your doctor can name the problem, the study, past health, and the question. The problem might involve appetite, a skin change, tiredness, or low desire. The study needs to describe a change that matters for that problem. Past health includes current medicines, previous illness, symptoms, and treatments already tried. The question may ask what else could explain the symptom or what further checks would help.
A hoped-for improvement is easier to assess when the doctor understands your starting health.
Weight and blood-sugar questions have large drug trials, with prescription risks to consider. For skin, the cream's ingredients and earlier irritation may change the answer. For tiredness, the doctor can investigate other causes before interpreting a NAD+ blood claim. Sexual problems may involve pain, relationships, desire, or heart health. The individual guides give more detail about the studies. The common questions explain early concerns, and the supporting sources link findings to their papers.